Bolt Biotherapeutics, Inc. (BOLT) NASDAQ
5.48
+0.09(+1.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.48
+0.09(+1.67%)
Currency In USD
| Previous Close | 5.39 |
| Open | 5.28 |
| Day High | 5.5 |
| Day Low | 5.1 |
| 52-Week High | 9.24 |
| 52-Week Low | 3.91 |
| Volume | 765.5 |
| Average Volume | 25,880 |
| Market Cap | 10.53M |
| PE | -0.31 |
| EPS | -17.85 |
| Moving Average 50 Days | 4.63 |
| Moving Average 200 Days | 5.32 |
| Change | 0.09 |
CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)
Newsfile
Oct 20, 2025 4:58 PM GMT
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
GlobeNewswire Inc.
Oct 01, 2025 8:05 PM GMT
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the tre